About Us | Contact

Dr. Eduardo Antonio Arazoza Investigator

Cardiovascular Disease Strong Memorial Hospital NPI1518937671
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$51,218.57
from 26 payments in the last 6 years

Total Cash or Cash Equivalent

$51,062.50
from 24 payments in the last 6 years

Total In-kind Items & Services

$156.07
from 2 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
01/11/2019 Research Cash or cash equivalent $375.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 689938279
03/02/2019 General (Non-Research) In-kind items and services Food and Beverage $59.49 Details
Payment from Medtronic Vascular, Inc.
Payment Record ID 676885791
12/13/2018 Research Cash or cash equivalent $1625.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315491
11/18/2018 Research Cash or cash equivalent $1500.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315487
10/06/2018 Research Cash or cash equivalent $625.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315485
09/19/2018 Research Cash or cash equivalent $1312.50 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315479
08/09/2018 Research Cash or cash equivalent $1125.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315477
07/06/2018 Research Cash or cash equivalent $1875.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315473
06/07/2018 Research Cash or cash equivalent $1500.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315469
05/09/2018 Research Cash or cash equivalent $312.50 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315467
04/03/2018 Research Cash or cash equivalent $62.50 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315465
03/12/2018 Research Cash or cash equivalent $687.50 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315463
02/07/2018 Research Cash or cash equivalent $1562.50 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 613315459
01/10/2018 Research Cash or cash equivalent $2125.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02260804
Payment Record ID 610896757
01/10/2018 Research Cash or cash equivalent Drug $7125.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP DOSE FINDING STUDY TO ASSESS THE EFFECT OF 3 DOSES OF LIK066 COMPARED TO PLACEBO OR EMPAGLIFLOZIN IN TYPE 2 DIABETES MELILTUS PATIENTS WITH HEART FAILURE
Payment Record ID 584630559
07/06/2018 Research Cash or cash equivalent Biological $500.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A 28 WEEK RANDOMIZED WITHDRAWAL EXTENSION OF A DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS DURABILITY OF EFFECT ON SKELETAL MUSCLE STRENGTH AND FUNCTION UPON WITHDRAWAL OF BIMAGRUMAB 70 210 700 MG IN OLDER ADULTS WITH SARCOPENIA
Payment Record ID 584630557
01/10/2018 Research Cash or cash equivalent Biological $2812.50 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE
Payment Record ID 584630555
08/09/2018 Research Cash or cash equivalent Biological $125.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A 28 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER PARALLEL GROUP DOSE RANGE FINDING STUDY TO ASSESS THE EFFECT OF MONTHLY DOSES OF BIMAGRUMAB 70 210 AND 700 MG ON SKELETAL MUSCLE STRENGTH AND FUNCTION IN OLDER ADULTS WITH SARCOPENIA
Payment Record ID 584630553
11/09/2017 Research Cash or cash equivalent $2062.50 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02162667
Payment Record ID 510250459
10/06/2017 Research Cash or cash equivalent $625.00 Details
Payment from Celltrion, Inc.
Paymment Research Study CT-P6 3.2
Clinical Trials Gov ID NCT02162667
Payment Record ID 510249097
09/12/2017 Research Cash or cash equivalent Drug $2562.50 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP DOSE FINDING STUDY TO ASSESS THE EFFECT OF 3 DOSES OF LIK066 COMPARED TO PLACEBO OR EMPAGLIFLOZIN IN TYPE 2 DIABETES MELILTUS PATIENTS WITH HEART FAILURE
Payment Record ID 489841117
03/09/2017 Research Cash or cash equivalent Biological $3937.50 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE
Payment Record ID 489834931
02/09/2017 Research Cash or cash equivalent Biological $3250.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study AN OPEN LABEL LONG TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS
Payment Record ID 489832589
06/28/2017 General (Non-Research) In-kind items and services Food and Beverage $96.58 Details
Payment from Shire North American Group Inc
Payment Record ID 466881555
01/07/2016 Research Cash or cash equivalent Biological $12812.50 Details
Payment from Novartis Pharmaceuticals Corporation
Paymment Research Study RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED DOSE FINDING STUDY TO EVALUATE EFFICACY SAFETY TOLERABILITY OF IV BYM338 AT 52 WEEKS ON PHYSICAL FUNCTION MUSCLE STRENGTH AND MOBILITY IN SPORADIC INCLUSION BODY MYOSITIS PATIENTS
Payment Record ID 407686580
01/07/2016 Research Cash or cash equivalent Biological $562.50 Details
Payment from Novartis Pharmaceuticals Corporation
Paymment Research Study AN OPEN LABEL LONG TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BYM338 IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS
Payment Record ID 407686574
;